Board of Directors
Steven Brugger — President and CEO, Affinivax
Steve Brugger brings over 30 years of experience in the biotech and pharmaceutical industry to Affinivax. He most recently served as the Chief Executive Officer of Visterra, a private biotech company based in Cambridge, Mass. During his tenure at Visterra, Steve led the company in closing a Series A round of financing, advancing its lead antibody program toward IND, and establishing strategic partnerships with both Pfizer and the Bill & Melinda Gates Foundation. Prior to Visterra, Steve was the Chief Operating Officer at Momenta Pharmaceuticals. While at Momenta, Steve held several leadership roles as the company grew from a private start-up to a successful public-traded biotechnology company. Prior to Momenta, Steve held various leadership and management positions at Millennium, Novartis, Ayerst, and Hoechst Pharmaceuticals. Steve received his BA in Biology from Susquehanna University and his MBA from the Rutgers Graduate School of Management.
Richard Malley, MD — Kenneth McIntosh Chair in Pediatric Infectious Diseases, Boston Children’s Hospital and Affinivax scientific founder
Richard Malley is Affinivax’s scientific founder and the Kenneth McIntosh Chair in Pediatric Infectious Diseases at Boston Children’s Hospital. He is also the Director of the Travel and Geographic Medicine Clinic at Boston Children’s Hospital. He runs an NIH-funded laboratory where his group focuses on various aspects of bacterial pathogenesis, natural- and vaccine-induced immunity and the development of novel vaccine technologies, such as the Multiple Antigen Presenting System (MAPS). As an experienced physician with more than 20 years of experience treating infectious diseases, Dr. Malley has led an international effort in the development of novel vaccines in collaboration with colleagues and global nonprofit health organizations such as PATH and the Bill and Melinda Gates Foundation.
George Siber, MD — Former Executive Vice President and Chief Scientific Officer of Wyeth Vaccines
George Siber has served as Executive Vice President and Chief Scientific Officer of Wyeth Vaccines, or Wyeth. While at Wyeth, Dr. Siber oversaw the development and approval of multiple widely-used childhood vaccines, including Prevnar, a pneumococcal vaccine which has achieved multibillion dollar revenues; Acel-Imune, an acellular pertussis vaccine; and Meningitec, a meningococcal meningitis vaccine. Prior to Wyeth, Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and a Harvard Medical School Associate Professor of Medicine at Dana Farber Cancer Institute. Dr. Siber holds an MD degree from McGill University in Canada, received post-doctoral training in Internal Medicine at Rush-Presbyterian Hospital in Chicago and Beth Israel Hospital in Boston and Infectious Disease and vaccinology training at Children’s Hospital and Beth Israel Hospital, Harvard Medical School Boston.
Frances Heller — Former Senior Vice President of Business Development, Bristol-Myers Squibb
Fran Heller has nearly 20 years of experience in the pharmaceutical and biotech industries in business development, licensing and legal affairs. Most recently, she was Senior Vice President of Business Development at Bristol-Myers Squibb and a Trustee of the Bristol-Myers Squibb Foundation. Ms Heller currently serves as a trustee of the Dana Farber Cancer Institute and as a member of the board of directors at Zafgen, Inc., a public biotech company. Prior to joining Bristol-Meyers Squibb, Ms. Heller was executive vice president of business development at Exelixis Pharmaceuticals and prior to joining Exelixis, Ms. Heller was head of strategic alliances at Novartis Pharmaceuticals. Ms. Heller is an instructor and guest lecturer at several universities as an expert in the business of strategy setting, deal making and negotiation. Ms. Heller is a member of the California State Bar and licensed by the U.S. Patent and Trademark Office. She holds a B.S. in biology from Tulane University, an M.A. in biology from American University and a J.D. from Golden Gate University School of Law.
Bob More — Former Senior Advisor, Program-Related Investments, the Bill & Melinda Gates Foundation
Bob More joined the Bill and Melinda Gates Foundation in 2013 and was a Senior Advisor working on Program Related Investments and leading the foundation’s Global Health Venture Capital initiative until May 2015. Previously, Bob was a Partner at Frazier Healthcare from 2008-2013 and a Partner at Domain Associates, having joined the firm in 1996 as a Kauffman Fellow and becoming a Partner in 2000. From 1997-1998, Bob served as the Chief Operating Officer of Small Molecule Therapeutics. Prior to attending business school, Bob held a Sales Position with Pharmacia and began his career in research at Somatogen, a start-up focused on a recombinant blood substitute. As a venture capitalist, Bob lead and oversaw investments in Biotechnology, Pharmaceuticals, Medical Devices and Health Care IT. Bob was a Founding Board Member of the Kauffman Fellows Program and serves on several outside boards. He also serves as Chairman of One Revolution, an organization focused on challenging perspectives on disabilities. Bob received his BA from Middlebury College and an MBA from the Darden School of Business Administration at the University of Virginia.
David Rossow — Senior Officer, Program-Related Investments, the Bill & Melinda Gates Foundation
David Rossow is a Senior Officer with the Program-Related Investments (PRI) team at the Bill & Melinda Gates Foundation, where he oversees strategic investments in global health, global development, and US education from the foundation’s $1.5B PRI pool. David is a board observer on the board of directors. David joined the foundation in 2010 as part of a $400M pilot to establish the PRI program and has since helped grow the portfolio to more than 40 investments comprising a range of structures, sectors, and geographies. Prior to joining the foundation, David worked on deal teams in private equity and investment banking, where he was responsible for executing leveraged buyout, equity, debt, restructuring and merger & acquisition transactions across a variety of industries. David holds a BA in economics with an emphasis in finance from St. Olaf College.